LOST MONEY IN GWG L BONDS? CLICK HERE TO LEARN MORE

NOTICE TO UBS CLIENTS WHO PURCHASED REVERSE CONVERTIBLE NOTES: The Securities Law Firm of KlaymanToskes has Commenced an Investigation in the Wake of $15 Million SEC Settlement

If you have lost money in the stock market due to fraud, misrepresentation, negligence, or for other reasons, we can help you. We have successfully recovered over $250 million in FINRA securities arbitrations.*

Need Legal Help? Contact Us. Call +1 (888) 997-9956
Updated on: September 29, 2016

New York, NY (Business Wire) – September 29, 2016 – The Securities Arbitration Law Firm of KlaymanToskes, www.klaymantoskes.com, announced today that it has commenced an investigation into UBS’ (NYSE:UBS) sales practices regarding reverse convertible notes, in light of the $15 million settlement UBS paid to the SEC.

These reverse convertible notes were derivative investments which were tied to individual stocks. According to the SEC, these notes were sold to more than 8,700 of UBS’s customers from 2011 to 2014, many of which were inexperienced and unsophisticated.  The notes were sold under a variety of different names such as:

Trigger Yield Optimization Notes

Trigger Autocall Optimization Securities

Trigger Phoenix Autocall Optimization Securities

Airbag Yield Optimization Securities

Airbag Autocallable Yield Optimization Notes

According to securities attorney Lawrence L. Klayman, “the scope of our investigation is related to reverse convertible notes which UBS sold to clients despite investment objectives and risk tolerances that should have prohibited such investments from being made.”  Additionally, Mr. Klayman explains, “UBS failed to adequately train and supervise its brokers in order to safeguard unsophisticated, risk averse investors from buying these unnecessarily risky reverse convertible notes.”

KlaymanToskes is investigating UBS’ conduct with respect to unsuitable recommendations, misrepresentations and omissions, and failure to supervise.  The investigation is focused on the adequacy of UBS’ supervisory system for the reverse convertible notes and the manner in which UBS’ representatives solicited investors to purchase these unsuitable investments.

The sole purpose of this release is to investigate the sales practices of UBS in connection with the sale of reverse convertible notes to their customers. Current and former customers of UBS who purchased reverse convertible notes that have information relating to the manner in which the firm represented these products, are encouraged to contact Lawrence L. Klayman, Esq. or Raymond Gentile, Esq. of KlaymanToskes at (888) 997-9956, or visit our website at www.klaymantoskes.com.